ESMO Asia Congress | Conference

Dr. Price on the Challenges of the CodeBreaK 100 Trial in GI Cancers

November 23rd 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses challenges faced during the CodeBreaK 100 trial in gastrointestinal cancers.

Dr. Chaft on the Rationale for the OPAL Trial in EGFR+ NSCLC

November 23rd 2020

Jamie E. Chaft, MD, discusses the rationale behind the OPAL trial in EGFR-mutant non–small cell lung cancer.

Sotorasib Displays Disease Control, Safety in KRAS G12C–Mutant Gastrointestinal Cancers

November 22nd 2020

Sotorasib was well tolerated and led to disease control in the majority of patients with heavily pretreated KRAS G12C–mutant gastrointestinal malignancies.

Sugemalimab/Chemo Combo Elicits Clinically Meaningful PFS Benefit in Metastatic NSCLC

November 21st 2020

November 21, 2020 - The addition of sugemalimab to chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit in the frontline treatment of patients with metastatic non–small cell lung cancer versus placebo plus chemotherapy.

Dr. Price on the Safety, Efficacy of AMG 510 in Advanced Gastrointestinal Cancers

November 21st 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses the safety and efficacy of AMG 510 in patients with advanced gastrointestinal cancers.

Dr. Perol on EGFR TKI/Chemotherapy Combinations in Advanced EGFR+ NSCLC

November 21st 2020

Maurice Perol, MD, discusses combination regimens comprised of chemotherapy and EGFR TKIs in the treatment of patients with EGFR-mutated advanced non–small cell lung cancer, as investigated in the OPAL trial presented during the ESMO Asia Virtual Congress 2020.

Sintilimab/Bevacizumab Biosimilar Combo Shows Superior OS, PFS Over Sorafenib in Advanced Unresectable HCC

November 21st 2020

November 21, 2020 - Frontline sintilimab injection in combination with bevacizumab biosimilar injection resulted in a significant improvement in overall survival and progression-free survival per Independent Radiographic Review Committee versus sorafenib in patients with advanced unresectable hepatocellular carcinoma.

Maintenance Niraparib, Given at Individualized Starting Dose, Improves PFS in Chinese Patients With Ovarian Cancer

November 21st 2020

November 21, 2020 — Maintenance niraparib, when administered at an individualized starting dose, led to a 70% reduction in the risk of disease progression or death compared with placebo in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy.

Atezolizumab/Nab-Paclitaxel Induces Clinically Meaningful OS Benefit in PD-L1+ Locally Advanced or Metastatic TNBC

November 20th 2020

The combination of atezolizumab and nab-paclitaxel led to a clinically meaningful overall survival benefit in treatment-naïve patients with locally advanced or metastatic triple-negative breast cancer who had PD-L1 expressing tumor-infiltrating immune cells.

Asian Patients With HR+, HER2- Breast Cancer Have Higher Risk of Recurrence, May Benefit From Additional Adjuvant Abemaciclib

November 20th 2020

November 20, 2020 - Patients from Asian countries with hormone receptor–positive, HER2-negative breast cancer may have a higher risk of disease recurrence than those from non-Asian countries, suggesting that this population may benefit from additional adjuvant treatment with abemaciclib.